Search

Your search keyword '"Raghav, Kanwal"' showing total 862 results
Start Over Author "Raghav, Kanwal"
862 results on '"Raghav, Kanwal"'

2. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Author

Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev, Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore, and DESTINY-CRC01 investigators

Subjects
DESTINY-CRC01 investigators, Humans, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Camptothecin, Receptor, erbB-2, Immunoconjugates, Female, Antibodies, Monoclonal, Humanized, Trastuzumab, Receptor, ErbB-2, Clinical Research, Clinical Trials and Supportive Activities, Colo-Rectal Cancer, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals
Abstract

DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.

Published
2023

3. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit

Author

Bhutiani, Neal, Grotz, Travis E., Concors, Seth J., White, Michael G., Helmink, Beth A., Raghav, Kanwal P., Taggart, Melissa W., Beaty, Karen A., Royal, Richard E., Overman, Michael J., Matamoros, Aurelio, Scally, Christopher P., Rafeeq, Safia, Mansfield, Paul F., and Fournier, Keith F.

Published
2024
Full Text
View/download PDF

5. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Author

Raghav, Kanwal, Siena, Salvatore, Takashima, Atsuo, Kato, Takeshi, Van den Eynde, Marc, Pietrantonio, Filippo, Komatsu, Yoshito, Kawakami, Hisato, Peeters, Marc, Andre, Thierry, Lonardi, Sara, Yamaguchi, Kensei, Tie, Jeanne, Castro, Cristina Gravalos, Hsu, Hung-Chih, Strickler, John H, Kim, Tae-You, Cha, Yongjun, Barrios, Daniel, Yan, Qi, Kamio, Takahiro, Kobayashi, Kojiro, Boran, Aislyn, Koga, Makito, Allard, John D, and Yoshino, Takayuki

Published
2024
Full Text
View/download PDF

6. Survival improvement for patients with metastatic colorectal cancer over twenty years

Author

Zeineddine, Fadl A., Zeineddine, Mohammad A., Yousef, Abdelrahman, Gu, Yue, Chowdhury, Saikat, Dasari, Arvind, Huey, Ryan W., Johnson, Benny, Kee, Bryan, Lee, Michael S., Morelli, Maria Pia, Morris, Van K., Overman, Michael J., Parseghian, Christine, Raghav, Kanwal, Willis, Jason, Wolff, Robert A., Kawaguchi, Yoshikuni, Vauthey, Jean-Nicolas, Sun, Ryan, Kopetz, Scott, and Shen, John Paul

Published
2023
Full Text
View/download PDF

9. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

Author

Dasari, Arvind, Morris, Van K, Allegra, Carmen J, Atreya, Chloe, Benson, Al B, Boland, Patrick, Chung, Ki, Copur, Mehmet S, Corcoran, Ryan B, Deming, Dustin A, Dwyer, Andrea, Diehn, Maximilian, Eng, Cathy, George, Thomas J, Gollub, Marc J, Goodwin, Rachel A, Hamilton, Stanley R, Hechtman, Jaclyn F, Hochster, Howard, Hong, Theodore S, Innocenti, Federico, Iqbal, Atif, Jacobs, Samuel A, Kennecke, Hagen F, Lee, James J, Lieu, Christopher H, Lenz, Heinz-Josef, Lindwasser, O Wolf, Montagut, Clara, Odisio, Bruno, Ou, Fang-Shu, Porter, Laura, Raghav, Kanwal, Schrag, Deborah, Scott, Aaron J, Shi, Qian, Strickler, John H, Venook, Alan, Yaeger, Rona, Yothers, Greg, You, Y Nancy, Zell, Jason A, and Kopetz, Scott

Subjects
Cancer, Clinical Research, Colo-Rectal Cancer, Digestive Diseases, Good Health and Well Being, Biomarkers, Tumor, Circulating Tumor DNA, Colon, Colorectal Neoplasms, Humans, Liquid Biopsy, National Cancer Institute (U.S.), Neoplasm, Residual, Rectal Neoplasms, United States, Oncology and Carcinogenesis
Abstract

An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal-Anal Task Forces of the United States National Cancer Institute convened a panel of multidisciplinary experts to summarize current data on the utility of ctDNA in the management of colorectal cancer and to provide guidance in promoting the efficient development and integration of this technology into clinical care. The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments. The panel also provides general guidelines with relevance for ctDNA-related research efforts, irrespective of indication.

Published
2020

10. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Author

Fakih, Marwan, Raghav, Kanwal Pratap Singh, Chang, David Z., Larson, Tim, Cohn, Allen L., Huyck, Timothy K., Cosgrove, David, Fiorillo, Joseph A., Tam, Rachel, D'Adamo, David, Sharma, Neelesh, Brennan, Barbara J., Wang, Ying A., Coppieters, Sabine, Zebger-Gong, Hong, Weispfenning, Anke, Seidel, Henrik, Ploeger, Bart A., Mueller, Udo, Oliveira, Carolina Soares Viana de, and Paulson, Andrew Scott

Published
2023
Full Text
View/download PDF

12. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D.

Author

Raghav, Kanwal Pratap Singh, primary, Xiao, Lianchun, additional, Lewis, Courtney, additional, Zeller, Brittany E, additional, Overman, Michael J., additional, Huey, Ryan W, additional, Dasari, Arvind, additional, Chang, Kyle, additional, Quinn, Katie, additional, Shen, John Paul Y.C., additional, Parseghian, Christine Megerdichian, additional, Willis, Jason, additional, Ludford, Kaysia, additional, Morris, Van K., additional, Wolff, Robert A., additional, Wang, Xin Shelley, additional, Drusbosky, Leylah, additional, and Kopetz, Scott, additional

Published
2024
Full Text
View/download PDF

13. Clinical and pathological characteristics of cancer of unknown primary with renal profile using gene expression profiling (GEP)–based cancer classification.

Author

Allam, Joelle, primary, Ma, Li, additional, Zhao, Jianping, additional, Estrella, Jeannelyn, additional, Higbie, Victoria, additional, Willett, Anneleis, additional, Matamoros, Aurelio, additional, Lano, Elizabeth A, additional, Treuner, Kai, additional, Raghav, Kanwal Pratap Singh, additional, and Huey, Ryan W, additional

Published
2024
Full Text
View/download PDF

14. First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.

Author

Sharma, Manish, primary, Strickler, John H, additional, Sommerhalder, David, additional, Kuboki, Yasutoshi, additional, Perets, Ruth, additional, Cohen, Jonathan, additional, Raimbourg, Judith, additional, Nakajima, Takako Eguchi, additional, Yamamoto, Noboru, additional, Cruz-Correa, Marcia, additional, O'Neil, Bert, additional, Ghiringhelli, François, additional, Raghav, Kanwal Pratap Singh, additional, Li, Rui, additional, Morrison Thiele, Gladys, additional, Neagu Aristide, Martha Raluca, additional, Freise, Kevin Jay, additional, Biesdorf de Almeida, Carla, additional, Vasilopoulos, Athanasios, additional, and Powderly, John D., additional

Published
2024
Full Text
View/download PDF

15. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.

Author

Pellatt, Andrew Jared, primary, Maddalena, Giulia, additional, Bent, Alisha Heather, additional, Parseghian, Christine Megerdichian, additional, Huey, Ryan W, additional, Raghav, Kanwal Pratap Singh, additional, Morris, Van K., additional, Overman, Michael J., additional, Morelli, Maria Pia, additional, Willis, Jason, additional, Le, Phat, additional, Shen, John Paul Y.C., additional, Alfaro, Kristin, additional, Aziz, Kathryn, additional, Kell, Robert J., additional, Sun, Ryan, additional, Kopetz, Scott, additional, and Dasari, Arvind, additional

Published
2024
Full Text
View/download PDF

16. Racial/ethnic representation and disparities in preclinical cancer models.

Author

Loree, Jonathan M., primary, Dasari, Arvind, additional, Willis, Jason, additional, Gothwal, Himanish, additional, Shaheed, Mena, additional, Singh, Kulwinder, additional, Shaheed, Hewad, additional, Mangal, Riya, additional, Gothwal, Shivek, additional, Pant, Anya, additional, Overman, Michael J., additional, Kopetz, Scott, additional, and Raghav, Kanwal Pratap Singh, additional

Published
2024
Full Text
View/download PDF

17. Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

18. Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Tables from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

20. TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

21. Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Author

Hornstein, Nicholas J., primary, Zeineddine, Mohammad A., primary, Gunes, Betul B., primary, Pellatt, Andrew J., primary, Knafl, Mark, primary, Zhu, Haifeng, primary, Willett, Anneleis F., primary, Yousef, Abdelrahman, primary, Liu, Suyu, primary, Sun, Ryan, primary, Futreal, Andrew, primary, Woodman, Scott E., primary, Taggart, Melissa W., primary, Overman, Michael J., primary, Halperin, Daniel M., primary, Raghav, Kanwal P., primary, and Shen, John Paul, primary

Published
2024
Full Text
View/download PDF

22. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Author

Meric-Bernstam, Funda, Beeram, Muralidhar, Hamilton, Erika, Oh, Do-Youn, Hanna, Diana L, Kang, Yoon-Koo, Elimova, Elena, Chaves, Jorge, Goodwin, Rachel, Lee, Jeeyun, Nabell, Lisle, Rha, Sun Young, Mayordomo, Jose, El-Khoueiry, Anthony, Pant, Shubham, Raghav, Kanwal, Kim, Jin Won, Patnaik, Amita, Gray, Todd, Davies, Rupert, Ozog, Mark A, Woolery, Joseph, and Lee, Keun-Wook

Published
2022
Full Text
View/download PDF

23. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Author

Kaseb, Ahmed O, Sánchez, Nora S, Sen, Shiraj, Kelley, Robin K, Tan, Benjamin, Bocobo, Andrea G, Lim, Kian H, Abdel-Wahab, Reham, Uemura, Marc, Pestana, Roberto Carmagnani, Qiao, Wei, Xiao, Lianchun, Morris, Jeffrey, Amin, Hesham M, Hassan, Manal M, Rashid, Asif, Banks, Kimberly C, Lanman, Richard B, Talasaz, AmirAli, Mills-Shaw, Kenna R, George, Bhawana, Haque, Abedul, Raghav, Kanwal PS, Wolff, Robert A, Yao, James C, Meric-Bernstam, Funda, Ikeda, Sadakatsu, and Kurzrock, Razelle

Subjects
Liver Disease, Genetics, Digestive Diseases, Genetic Testing, Human Genome, Hepatitis - B, Clinical Research, Liver Cancer, Rare Diseases, Hepatitis, Biotechnology, Cancer, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Hepatocellular, Circulating Tumor DNA, Clinical Decision-Making, Cohort Studies, DNA Mutational Analysis, Female, Gene Frequency, High-Throughput Nucleotide Sequencing, Humans, Liver Neoplasms, Male, Middle Aged, Mutation, Patient Selection, Prognosis, United States, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMolecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular carcinoma (HCC) given the challenge of obtaining liver tissue biopsies.Experimental designWe analyzed blood samples from 206 patients with HCC using comprehensive genomic testing (Guardant Health) of circulating tumor DNA (ctDNA).ResultsA total of 153/206 (74.3%) were men; median age, 62 years (range, 18-91 years). A total of 181/206 patients had ≥1 alteration. The total number of alterations was 680 (nonunique); median number of alterations/patient was three (range, 1-13); median mutant allele frequency (% cfDNA), 0.49% (range, 0.06%-55.03%). TP53 was the common altered gene [>120 alterations (non-unique)] followed by EGFR, MET, ARID1A, MYC, NF1, BRAF, and ERBB2 [20-38 alterations (nonunique)/gene]. Of the patients with alterations, 56.9% (103/181) had ≥1 actionable alterations, most commonly in MYC, EGFR, ERBB2, BRAF, CCNE1, MET, PIK3CA, ARID1A, CDK6, and KRAS. In these genes, amplifications occurred more frequently than mutations. Hepatitis B (HBV)-positive patients were more likely to have ERBB2 alterations, 35.7% (5/14) versus 8.8% HBV-negative (P = 0.04).ConclusionsThis study represents the first large-scale analysis of blood-derived ctDNA in HCC in United States. The genomic distinction based on HCC risk factors and the high percentage of potentially actionable genomic alterations suggests potential clinical utility for this technology.

Published
2019

24. Circulating Tumor DNA as a Marker of Minimal Residual Disease

Author

Fangman, Ben, Raghav, Kanwal, and Kopetz, Scott

Subjects
DNA -- Health aspects, Colorectal cancer -- Risk factors, Cancer -- Care and treatment -- Risk factors, Health
Abstract

Colorectal cancer (CRC) remains the third most common cancer and second most common cause of cancer death in the United States. (1) Traditionally, treatment and prognostication have been based on [...]

Published
2022

25. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

Author

Newhook, Timothy E., Overman, Michael J., Chun, Yun Shin, Dasari, Arvind, Tzeng, Ching-Wei D., Cao, Hop S. Tran, Raymond, Victoria, Parseghian, Christine, Johnson, Benny, Nishioka, Yujiro, Kawaguchi, Yoshikuni, Uppal, Abhineet, Vreeland, Timothy J., Jaimovich, Ariel, Arvide, Elsa M., Cristo, Jenilette V., Wei, Steven H., Raghav, Kanwal P., Morris, Van K., Lee, Jeffrey E., Kopetz, Scott, and Vauthey, Jean-Nicolas

Published
2023
Full Text
View/download PDF

26. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean-Nicolas, Lee, Sunyoung S, Yavuz, Betul Gok, Mohamed, Yehia I, Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S, Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching-Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C, Wolff, Robert A, Allison, James Patrick, and Sharma, Padmanee

Published
2022
Full Text
View/download PDF

27. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer

Author

Taku, Nicolette, Yi-Qian, Y. Nancy, Chang, George J., Ludmir, Ethan B., Raghav, Kanwal Pratap Singh, Rodriguez-Bigas, Miguel A., Holliday, Emma Brey, Smith, Grace L., Minsky, Bruce D., Overman, Michael J., Messick, Craig, Boyce-Fappiano, David, Koong, Albert C., Skibber, John Michael, Koay, Eugene Jon, Dasari, Arvind, Taniguchi, Cullen M., Bednarski, Brian K., Morris, Van K., Kopetz, Scott, and Das, Prajnan

Published
2022
Full Text
View/download PDF

28. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma

Author

Yousef, Abdelrahman, primary, Yousef, Mahmoud, additional, Zeineddine, Mohammad A., additional, More, Aditya, additional, Fanaeian, Mohammad, additional, Chowdhury, Saikat, additional, Knafl, Mark, additional, Edelkamp, Paul, additional, Ito, Ichiaki, additional, Gu, Yue, additional, Pattalachinti, Vinay, additional, Naini, Zahra Alavi, additional, Zeineddine, Fadl A., additional, Peterson, Jennifer, additional, Alfaro, Kristin, additional, Foo, Wai Chin, additional, Jin, Jeff, additional, Bhutiani, Neal, additional, Higbie, Victoria, additional, Scally, Christopher P., additional, Kee, Bryan, additional, Kopetz, Scott, additional, Goldstein, Drew, additional, Strach, Madeleine, additional, Williamson, Andrew, additional, Aziz, Omer, additional, Barriuso, Jorge, additional, Uppal, Abhineet, additional, White, Michael G., additional, Helmink, Beth, additional, Fournier, Keith F., additional, Raghav, Kanwal P., additional, Taggart, Melissa W., additional, Overman, Michael J., additional, and Shen, John Paul, additional

Published
2024
Full Text
View/download PDF

29. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling

Author

Johnson, Benny, primary, Morris, Van, additional, Wang, Xuemei, additional, Dasari, Arvind, additional, Raghav, Kanwal, additional, Shen, John Paul, additional, Lee, Michael S., additional, Huey, Ryan, additional, Parseghian, Christine, additional, Willis, Jason, additional, Wolff, Robert, additional, Drusbosky, Leylah M., additional, Overman, Michael J., additional, and Kopetz, Scott, additional

Published
2024
Full Text
View/download PDF

30. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Author

Siena, Salvatore, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Fakih, Marwan, Elez, Elena, Rodriguez, Javier, Ciardiello, Fortunato, Komatsu, Yoshito, Esaki, Taito, Chung, Ki, Wainberg, Zev, Sartore-Bianchi, Andrea, Saxena, Kapil, Yamamoto, Eriko, Bako, Emarjola, Okuda, Yasuyuki, Shahidi, Javad, Grothey, Axel, and Yoshino, Takayuki

Published
2021
Full Text
View/download PDF

34. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

Author

Piha-Paul, Sarina A, primary, Xu, Binghe, additional, Dumbrava, Ecaterina E, additional, Fu, Siqing, additional, Karp, Daniel D, additional, Meric-Bernstam, Funda, additional, Hong, David S, additional, Rodon, Jordi A, additional, Tsimberidou, Apostolia M, additional, Raghav, Kanwal, additional, Ajani, Jaffer A, additional, Conley, Anthony P, additional, Mott, Frank, additional, Fan, Ying, additional, Fan, Jean, additional, Peng, Peng, additional, Wang, Hui, additional, Ni, Shumao, additional, Sun, Caixia, additional, Qiang, Xiaoyan, additional, Levin, Wendy J, additional, Ngo, Brenda, additional, Ru, Qinhua Cindy, additional, Wu, Frank, additional, and Javle, Milind M, additional

Published
2024
Full Text
View/download PDF

35. Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.

Author

Oberstein, Paul Eliezer, primary, Moreno, Victor, additional, Raghav, Kanwal Pratap Singh, additional, Hong, Yong Sang, additional, Han, Sae-Won, additional, Su, Yu-Li, additional, Yuan, Ying, additional, Pietrantonio, Filippo, additional, Van Cutsem, Eric, additional, Eng, Cathy, additional, Curtin, Joshua C, additional, Chowdhury, Sanjib, additional, Bhattacharya, Rianka, additional, Maul, Raymond Scott, additional, Iwasawa, Ryota, additional, Schnepp, Robert W., additional, Knoblauch, Roland Elmar, additional, Thayu, Meena, additional, Ho, Gwo Fuang, additional, and Kim, Han Sang, additional

Published
2024
Full Text
View/download PDF

36. Understanding causes of racial/ethnic survival disparity in 47,178 patients with colorectal cancer: A quantitative evaluation of molecular, socioeconomic, and clinical covariates.

Author

Yousef, Mahmoud M.G., primary, Yousef, Abdelrahman M.G., additional, Fanaeian, Mohammad Mahdi, additional, Chowdhury, Saikat, additional, Knafl, Mark, additional, Zeineddine, Mohammad, additional, Alfaro, Kristin, additional, Uppal, Abhineet, additional, Sun, Ryan, additional, Wang, Wenyi, additional, Raghav, Kanwal Pratap Singh, additional, Willis, Jason, additional, Kopetz, Scott, additional, and Shen, John Paul Y.C., additional

Published
2024
Full Text
View/download PDF

37. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations.

Author

Bhamidipati, Deepak, primary, Haro-Silerio, Jaime, additional, Dumbrava, Ecaterina Elena, additional, Fu, Siqing, additional, Hong, David S., additional, Karp, Daniel D., additional, Naing, Aung, additional, Pant, Shubham, additional, Piha-Paul, Sarina A., additional, Rodon Ahnert, Jordi, additional, Tsimberidou, Apostolia Maria, additional, Johnson, Amber, additional, Lee, Michael Sangmin, additional, Dasari, Arvind, additional, Raghav, Kanwal Pratap Singh, additional, Morris, Van K., additional, Overman, Michael J., additional, Kopetz, Scott, additional, Meric-Bernstam, Funda, additional, and Yap, Timothy A., additional

Published
2024
Full Text
View/download PDF

38. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.

Author

Pellatt, Andrew Jared, primary, Bent, Alisha Heather, additional, Parseghian, Christine Megerdichian, additional, Johnson, Benny, additional, Huey, Ryan W, additional, Raghav, Kanwal Pratap Singh, additional, Morris, Van K., additional, Overman, Michael J., additional, Morelli, Maria Pia, additional, Willis, Jason, additional, Le, Phat, additional, Shen, John Paul Y.C., additional, Lee, Michael Sangmin, additional, Alfaro, Kristin, additional, Aziz, Kathryn, additional, Kell, Robert J., additional, Sun, Ryan, additional, Kopetz, Scott, additional, and Dasari, Arvind, additional

Published
2024
Full Text
View/download PDF

39. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.

Author

Pellatt, Andrew Jared, primary, Maddalena, Giulia, additional, Eluri, Madhulika, additional, Parseghian, Christine Megerdichian, additional, Aziz, Kathryn, additional, Alfaro, Kristin, additional, Kell, Robert J., additional, Bent, Alisha Heather, additional, Huey, Ryan W, additional, Uppal, Abhineet, additional, Konishi, Tsuyoshi, additional, Overman, Michael J., additional, Morelli, Maria Pia, additional, Willis, Jason, additional, Shen, John Paul Y.C., additional, Raghav, Kanwal Pratap Singh, additional, Newhook, Timothy E., additional, Morris, Van K., additional, Dasari, Arvind, additional, and Kopetz, Scott, additional

Published
2024
Full Text
View/download PDF

40. Utility of gene expression–based cancer classification in diagnosis of malignant peritoneal mesothelioma (MPeM): Filling in the gaps in standard pathologic work-up for a rare cancer.

Author

Allam, Joelle, primary, Ma, Li, additional, Estrella, Jeannelyn, additional, Willett, Anneleis, additional, Beaty, Karen A., additional, Matamoros, Aurelio, additional, Lano, Elizabeth A, additional, Fournier, Keith F., additional, Treuner, Kai, additional, Raghav, Kanwal Pratap Singh, additional, and Huey, Ryan W, additional

Published
2024
Full Text
View/download PDF

41. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis.

Author

Higbie, Victoria, primary, Shah, Preksha, additional, Bent, Alisha Heather, additional, Dasari, Arvind, additional, Huey, Ryan W, additional, Johnson, Benny, additional, Kee, Bryan K., additional, Kopetz, Scott, additional, Lee, Michael Sangmin, additional, Ludford, Kaysia, additional, Morelli, Maria Pia, additional, Morris, Van K., additional, Parseghian, Christine Megerdichian, additional, Raghav, Kanwal Pratap Singh, additional, Shen, John Paul Y.C., additional, Willis, Jason, additional, Wolff, Robert A., additional, and Overman, Michael J., additional

Published
2024
Full Text
View/download PDF

43. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.

Author

Maddalena, Giulia, primary, Pellatt, Andrew Jared, additional, Eluri, Madhulika, additional, Parseghian, Christine Megerdichian, additional, Aziz, Kathryn, additional, Alfaro, Kristin, additional, Kell, Robert J., additional, Bent, Alisha Heather, additional, Huey, Ryan W, additional, Uppal, Abhineet, additional, Konishi, Tsuyoshi, additional, Overman, Michael J., additional, Morelli, Maria Pia, additional, Willis, Jason, additional, Shen, John Paul Y.C., additional, Raghav, Kanwal Pratap Singh, additional, Newhook, Timothy E., additional, Morris, Van K., additional, Dasari, Arvind, additional, and Kopetz, Scott, additional

Published
2024
Full Text
View/download PDF

44. Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC).

Author

Loree, Jonathan M., primary, Bubie, Adrian, additional, Eluri, Madhulika, additional, Parseghian, Christine Megerdichian, additional, Overman, Michael J., additional, Zhang, Nicole, additional, Drusbosky, Leylah, additional, Kopetz, Scott, additional, and Raghav, Kanwal Pratap Singh, additional

Published
2024
Full Text
View/download PDF

45. TABLE 2 from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Author

Simmons, Kristen, primary, Thomas, Jane V., primary, Ludford, Kaysia, primary, Willis, Jason A., primary, Higbie, Victoria S., primary, Raghav, Kanwal P.S., primary, Johnson, Benny, primary, Dasari, Arvind, primary, Kee, Bryan K., primary, Parseghian, Christine M., primary, Lee, Michael S., primary, Le, Phat H., primary, Morelli, Maria P., primary, Shen, John Paul, primary, Bent, Alisha, primary, Vilar, Eduardo, primary, Wolff, Robert A., primary, Kopetz, Scott, primary, Overman, Michael J., primary, and Morris, Van Karlyle, primary

Published
2023
Full Text
View/download PDF

46. TABLE 1 from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Author

Simmons, Kristen, primary, Thomas, Jane V., primary, Ludford, Kaysia, primary, Willis, Jason A., primary, Higbie, Victoria S., primary, Raghav, Kanwal P.S., primary, Johnson, Benny, primary, Dasari, Arvind, primary, Kee, Bryan K., primary, Parseghian, Christine M., primary, Lee, Michael S., primary, Le, Phat H., primary, Morelli, Maria P., primary, Shen, John Paul, primary, Bent, Alisha, primary, Vilar, Eduardo, primary, Wolff, Robert A., primary, Kopetz, Scott, primary, Overman, Michael J., primary, and Morris, Van Karlyle, primary

Published
2023
Full Text
View/download PDF

47. FIGURE 3 from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Author

Simmons, Kristen, primary, Thomas, Jane V., primary, Ludford, Kaysia, primary, Willis, Jason A., primary, Higbie, Victoria S., primary, Raghav, Kanwal P.S., primary, Johnson, Benny, primary, Dasari, Arvind, primary, Kee, Bryan K., primary, Parseghian, Christine M., primary, Lee, Michael S., primary, Le, Phat H., primary, Morelli, Maria P., primary, Shen, John Paul, primary, Bent, Alisha, primary, Vilar, Eduardo, primary, Wolff, Robert A., primary, Kopetz, Scott, primary, Overman, Michael J., primary, and Morris, Van Karlyle, primary

Published
2023
Full Text
View/download PDF

48. FIGURE 4 from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Author

Simmons, Kristen, primary, Thomas, Jane V., primary, Ludford, Kaysia, primary, Willis, Jason A., primary, Higbie, Victoria S., primary, Raghav, Kanwal P.S., primary, Johnson, Benny, primary, Dasari, Arvind, primary, Kee, Bryan K., primary, Parseghian, Christine M., primary, Lee, Michael S., primary, Le, Phat H., primary, Morelli, Maria P., primary, Shen, John Paul, primary, Bent, Alisha, primary, Vilar, Eduardo, primary, Wolff, Robert A., primary, Kopetz, Scott, primary, Overman, Michael J., primary, and Morris, Van Karlyle, primary

Published
2023
Full Text
View/download PDF

49. Supplemental Figure S1 from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Author

Simmons, Kristen, primary, Thomas, Jane V., primary, Ludford, Kaysia, primary, Willis, Jason A., primary, Higbie, Victoria S., primary, Raghav, Kanwal P.S., primary, Johnson, Benny, primary, Dasari, Arvind, primary, Kee, Bryan K., primary, Parseghian, Christine M., primary, Lee, Michael S., primary, Le, Phat H., primary, Morelli, Maria P., primary, Shen, John Paul, primary, Bent, Alisha, primary, Vilar, Eduardo, primary, Wolff, Robert A., primary, Kopetz, Scott, primary, Overman, Michael J., primary, and Morris, Van Karlyle, primary

Published
2023
Full Text
View/download PDF

50. Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Author

Simmons, Kristen, primary, Thomas, Jane V., primary, Ludford, Kaysia, primary, Willis, Jason A., primary, Higbie, Victoria S., primary, Raghav, Kanwal P.S., primary, Johnson, Benny, primary, Dasari, Arvind, primary, Kee, Bryan K., primary, Parseghian, Christine M., primary, Lee, Michael S., primary, Le, Phat H., primary, Morelli, Maria P., primary, Shen, John Paul, primary, Bent, Alisha, primary, Vilar, Eduardo, primary, Wolff, Robert A., primary, Kopetz, Scott, primary, Overman, Michael J., primary, and Morris, Van Karlyle, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results